MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ
4.710
-0.020
-0.42%
After Hours: 4.730 +0.02 +0.42% 19:59 03/01 EST
OPEN
4.890
PREV CLOSE
4.730
HIGH
5.02
LOW
4.690
VOLUME
3.22M
TURNOVER
0
52 WEEK HIGH
6.93
52 WEEK LOW
1.210
MARKET CAP
3.16B
P/E (TTM)
-4.4999
1D
5D
1M
3M
1Y
5Y
ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
ImmunityBio's Anktiva's PDUFA date is April 23rd for the treatment of non-muscle-invasive bladder cancer. The company's stock is up 100% since my "Sell" recommendation in August. ImmunityBio secured a $300M deal with Infinity in January. The deal complicates the company's financial and regulatory risks.
Seeking Alpha · 5d ago
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Freshpet shares gained 15.5% to $106.29 on Monday. The company reported better-than-expected fourth-quarter financial results. Akili, Inc. Shares jumped 126% after the company reported positive results from a clinical trial of an ADHD drug in Japan.
Benzinga · 6d ago
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Intuitive Machines, Inc. Shares fell sharply in today's pre-market trading. The company's lunar lander, Odysseus, encountered a mishap during a touchdown near the moon's south pole. ZyVersa Therapeutics, Inc., and 23andMe Holding Co. Were among the stocks moving in pre- market trading.
Benzinga · 6d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
ZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 44.8% to $1.16 during Monday's pre-market session. Agiliti (NYSE:AGTI) shares moved upwards by 27.09%. Altimmune and ImmunityBio shares also rose during the session. Losers ThermoGenesis Holdings and Cogent Biosciences.
Benzinga · 6d ago
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Shares of Li Auto Inc. Rose sharply in today’s pre-market trading after the company reported fourth-quarter financial results above estimates. U.S. Stock futures were lower this morning, with the Dow futures trading lower by over 50 points. The company reported sales of $5.88 billion in the fourth quarter.
Benzinga · 6d ago
ImmunityBio Boosts Executive Compensation and Sets Incentives
TipRanks · 6d ago
Weekly Report: what happened at IBRX last week (0219-0223)?
Weekly Report · 6d ago
BIGC, IBRX and VNDA are among after hour movers
Seeking Alpha · 02/23 22:39
More
About IBRX
Immunitybio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its segment is focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Its platforms include antibody cytokine fusion proteins; DNA, RNA, and recombinant protein vaccine technologies, including self-amplifying RNA, second-generation adenovirus hAd5 vector and recombinant protein platforms; toll-like receptor activating adjuvants; natural killer (NK) cell therapy, including off-the-shelf NK cells, and autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK); damage-associated molecular patterns inducers, including Aldoxorubicin and Nanatinostat. Its clinical pipeline consists of over 26 clinical trials of which 17 are in Phase I or III development, across 13 indications in liquid and solid tumors.

Webull offers Immunitybio Inc stock information, including NASDAQ: IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.